{"id":199044,"date":"2025-06-20T05:27:17","date_gmt":"2025-06-20T05:27:17","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/199044\/"},"modified":"2025-06-20T05:27:17","modified_gmt":"2025-06-20T05:27:17","slug":"stock-market-live-updates-20-june-2025-sensex-nifty-open-marginally-higher-amid-israel-iran-conflict","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/199044\/","title":{"rendered":"Stock Market Live Updates 20 June 2025: Sensex, Nifty open marginally higher amid Israel-Iran conflict"},"content":{"rendered":"

Chris Wood of Jefferies<\/strong><\/p>\n

Some adjustments in India portfolio<\/p>\n

Investments in L&T, Thermax & Godrej Prop will be removed & replaced by TVS, Home First Fin & Manappuram Fin with 4% each<\/p>\n

Additional 1% each will be added to existing investments in PB Fin & Bharti Airtel<\/p>\n

Bernstein on Project Financing Norms<\/p>\n

RBI eases provisioning norms for under-construction projects<\/p>\n

Standard asset provision cut to 1% \u2013 major relief for lenders<\/p>\n

Relaxed norms + rate cuts + liquidity = lending boost ahead<\/p>\n

Guidelines lift sentiment for infra lending across sectors<\/p>\n

Specialized NBFCs like REC, PFC among key gainers<\/p>\n

PSU banks also poised to benefit from lower capital strain<\/p>\n

CITI on Project Financing Norms<\/strong><\/p>\n

RBI relaxes general provisioning norms for project finance<\/p>\n

Final norms seen as lender-friendly; effective from Oct 1, 2025<\/p>\n

Provisioning eased for infra & non-infra projects, incl. CRE<\/p>\n

Big relief for corporate lenders, especially PSU banks & infra NBFCs<\/p>\n

Eases concerns over cost overruns, potential pullback in funding<\/p>\n

Supports continued lender interest in project finance space<\/p>\n

EMKAY on Project Financing Norms<\/strong><\/p>\n

RBI takes pragmatic route with final project finance norms<\/p>\n

Provisioning for under-construction infra\/CRE projects at 1-1.25% vs 5% draft<\/p>\n

Eases pressure on project lenders like REC and PFC<\/p>\n

Flexible stance on DCCO delays, cost overruns, resolution triggers<\/p>\n

Limited PAT\/net worth impact; regulatory capital hit only from FY27<\/p>\n

Rate cuts + liquidity + relaxed norms may spur project lending<\/p>\n

Large PSBs, PFC, REC seen as key beneficiaries<\/p>\n

Jefferies on SBI<\/strong><\/p>\n

Maintain Buy with target price of Rs 960<\/p>\n

Growth soft now and expected to pickup in Q2\/Q3<\/p>\n

Aiming to sustain 1% ROA despite rate cuts<\/p>\n

Credit growth can stay higher than deposit growth; ramping-up on wealth offering<\/p>\n

Subsidiary businesses can improve<\/p>\n

MS on Banks<\/strong><\/p>\n

Play The Growth Recovery Via The \u2018High Five\u2019<\/p>\n

A Broad-Based Rally Post-RBI Easing Of Liquidity, Interest Rates & Regulations<\/p>\n

FY27 Would Be A Confluence Of Multiple Positives<\/p>\n

Next 2 Quarters Are Tough – A Buying Opportunity<\/p>\n

Believe Strong Banks Will See Significant Re-Rating<\/p>\n

Prefer \u2018High Five\u2019: ICICI Bank, Kotak Mahindra, AU SFB, HDFC Bank & Axis Bank<\/p>\n

At Large Private Banks, Expect Core Pre-Provision Operating Profit CAGR OF 16-18% Starting In FY27<\/p>\n

Citi on Jubilant FoodWorks<\/p>\n

Maintains buy with target price Rs 805<\/p>\n

Free delivery bundled with accelerated product innovation is driving higher frequency and new customer acquisition<\/p>\n

Company to build 5 platforms of Rs 10 billion each<\/p>\n

For Popeyes, gross margin at 100 stores will be broadly at par with competition<\/p>\n

Citi on Swiggy<\/p>\n

Retains Buy Swiggy with a target price of Rs 425<\/p>\n

Some leveling off on competitive spends in quick commerce in the last few months but remains early to call a trend<\/p>\n

QC marketing spends may stabilize here on Swiggy will likely prioritize MTU growth<\/p>\n

Food Delivery margins expansion hereon will be led by operating leverage, ad-monetization and operating efficiencies<\/p>\n

Jefferies on Infosys<\/p>\n

Maintain Buy with target price of Rs 1,660<\/p>\n

Delivery aligned by service lines to efficient scale up<\/p>\n

Delivery – a key source of competitive advantage<\/p>\n

Intensified focus on Risk management for large deals<\/p>\n

Al to usher in workforce transition<\/p>\n

BofA on Dr Reddy<\/strong><\/p>\n

Maintain Buy; Hike target price to Rs 1,500 from Rs 1,450<\/p>\n

Path to 25% margin – not as uphill<\/p>\n

Believe base business momentum & ability to optimize elevated cost base is underestimated<\/p>\n

H2CY25 has some key catalysts that will improve visibility on the high-value launches<\/p>\n

Tariff announcement is a near-term risk<\/p>\n

Nuvama on Aurobindo<\/strong><\/p>\n

Buy, target price Rs1,460 (cut from Rs1,485)<\/p>\n

Over the medium term, Aurobindo has triggers like resumption of the Pen-G unit, launches in Europe from China unit, injectable drug launches from Eugia-5, normalisation of supplies from Eugia-3, and volume growth in oral products<\/p>\n

Dip in gRevlimid shall be offset by growth in Europe and US launches<\/p>\n

Building in revenue\/EBITDA\/PAT CAGR of 7%\/8%\/15% over FY25-27E<\/p>\n

Stock is trading at 13.9x FY27E EPS, 16% discount to its five-year average<\/p>\n

Antique on Shilpa Medicare<\/strong><\/p>\n

Buy, target price Rs1,090<\/p>\n

Believe SLPA is entering a pivotal growth phase with both near-term execution and long-term strategic bets aligning to<\/p>\n

drive a multi-year growth cycle<\/p>\n

In the near term, SLPA is poised to capitalize on its differentiated formulations pipeline across key global markets<\/p>\n

Within its API segment, SLPA has been filing dossiers in regulated markets where volume offtake is likely to improve along with significant improvement in realization and profitability<\/p>\n

The biosimilars and CDMO biologics businesses have the potential to meaningfully contribute from FY28E onwards with a robust development pipeline and EU-GMP approved facility<\/p>\n

Company\u2019s pipeline monetization can lead to revenue growth<\/p>\n

CAGR of ~34% over a two-year period with EBITDA margin of ~34% by FY27E and EPS CAGR of over 100%<\/p>\n

Jefferies On Pharma<\/strong><\/p>\n

Cipla Regains Share In Albuterol, Gains In A Low-competition Injectable<\/p>\n

Lupin Faces New Rivals In Rivaroxaban (2.5mg)<\/p>\n

Sun Pharma Sees YoY Growth In Ilumya, Cequa; Gains In Vyvanse<\/p>\n

DRL Loses Share In gVascepa, gCiprodex<\/p>\n

gAptiomsees Multiple Generic Entries Despite 180-day Exclusivity<\/p>\n

BOFA Sec On Siemens<\/strong><\/p>\n

Maintain Underperform, TP Rs2,564<\/p>\n

Siemens Energy India Trades At A Premium Vs Peers<\/p>\n

Siemens (Ex-Energy) Is Expensive At 56x FY27; Maintain Underperform<\/p>\n

Core Business Faces Weak Private Capex<\/p>\n

Growth Driven By Public Capex & Mobility Despite Execution Challenges<\/p>\n

Digital Margin Under Pressure, Recovery Depends On Mobility & Smart Infra Growth<\/p>\n","protected":false},"excerpt":{"rendered":"Chris Wood of Jefferies Some adjustments in India portfolio Investments in L&T, Thermax & Godrej Prop will be…\n","protected":false},"author":2,"featured_media":199045,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3091],"tags":[80573,80567,78971,80586,51,79688,80589,327,30632,80575,80583,3128,80585,80579,80584,75257,7036,80578,3151,2441,80566,3130,80571,80572,80570,73364,80582,78972,3129,31283,80581,80569,79683,79682,80574,6638,45533,80576,80568,78969,80577,80587,22670,12706,7063,80588,76538,80580,79695,79696,79693,16,15],"class_list":{"0":"post-199044","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-bank-nifty-prediction-today","9":"tag-bombay-stock-exchange","10":"tag-bse","11":"tag-bse-stock-market-trends","12":"tag-business","13":"tag-buzzing-stocks","14":"tag-day-trading-guide","15":"tag-gold","16":"tag-gold-prices","17":"tag-india-stock-market-today","18":"tag-indian-equity-market-news","19":"tag-indian-stock-market","20":"tag-indian-stock-market-forecast","21":"tag-indian-stock-market-news","22":"tag-indian-stock-market-research","23":"tag-indian-stock-market-tips","24":"tag-market","25":"tag-market-live","26":"tag-market-news","27":"tag-markets","28":"tag-national-stock-exchange","29":"tag-nifty","30":"tag-nifty-50","31":"tag-nifty-prediction-today","32":"tag-nifty-technical-analysis","33":"tag-nifty-today","34":"tag-nifty-updates","35":"tag-nse","36":"tag-sensex","37":"tag-sensex-today","38":"tag-sensex-updates","39":"tag-share-market-live-today","40":"tag-share-market-live-updates","41":"tag-share-market-today","42":"tag-share-prices","43":"tag-shares","44":"tag-stock-exchanges","45":"tag-stock-market-analysis","46":"tag-stock-market-live-today","47":"tag-stock-market-live-updates","48":"tag-stock-market-prediction","49":"tag-stock-market-recommendations","50":"tag-stock-market-today","51":"tag-stock-prices","52":"tag-stocks","53":"tag-stocks-in-action","54":"tag-stocks-to-buy","55":"tag-stocks-to-buy-today","56":"tag-top-gainers-today","57":"tag-top-losers-today","58":"tag-trending-stocks","59":"tag-uk","60":"tag-united-kingdom"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/199044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=199044"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/199044\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/199045"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=199044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=199044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=199044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}